X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis
Fri, 29 Mar

ASTRAZENECA PHARMA has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

ASTRAZENECA PHARMA Income Statement Analysis

  • Operating income during the year rose 5.0% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 25.3% YoY during the fiscal. Operating profit margins witnessed a fall and down at 8.1% in FY18 as against 6.8% in FY17.
  • Depreciation charges decreased by 6.9% increased by 0.0% YoY, respectively.
  • Other income declined by 14.9% YoY.
  • Net profit for the year grew by 29.2% YoY.
  • Net profit margins during the year grew from 3.6% in FY17 to 4.4% in FY18.

ASTRAZENECA PHARMA Income Statement 2017-18

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
Net SalesRs m5,4375,7105.0%
Other incomeRs m144123-14.9%
Total RevenuesRs m5,5815,8334.5%
Gross profitRs m36946325.3%
DepreciationRs m158147-6.9%
InterestRs m000.0%
Profit before taxRs m35543823.4%
TaxRs m15517915.8%
Profit after taxRs m20125929.2%
Gross profit margin%6.88.1
Effective tax rate%43.540.8
Net profit margin%3.64.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



ASTRAZENECA PHARMA Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 2 billion as compared to Rs 2 billion in FY17, thereby witnessing an increase of 8.7%.
  • Current assets rose 28% and stood at Rs 3 billion, while fixed assets fell 14% and stood at Rs 790 million in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 5 billion as against Rs 4 billion during FY17, thereby witnessing a growth of 11%.

ASTRAZENECA PHARMA Balance Sheet as on March 2018

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
NetworthRs m2,2292,46910.8
 
Current LiabilitiesRs m1,9032,0708.7
Long-term DebtRs m000.0
Total LiabilitiesRs m4,1554,60510.8
 
Current assetsRs m2,5163,20927.6
Fixed AssetsRs m 917790-13.8
Total AssetsRs m4,1554,60510.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



ASTRAZENECA PHARMA Cash Flow Statement Analysis

  • ASTRAZENECA PHARMA's cash flow from operating activities (CFO) during FY18 stood at Rs 88 million on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs -94 million on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs 0 million, an improvement of 0% on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs -6 million from the Rs 384 million net cash flows seen during FY17.

ASTRAZENECA PHARMA Cash Flow Statement 2017-18

ParticularsNo. of months1212% Change
Year EndingMar-17Mar-18
Cash Flow from Operating ActivitiesRs m38188-76.9%
Cash Flow from Investing ActivitiesRs m3-94-
Cash Flow from Financing ActivitiesRs m000.0%
Net Cash FlowRs m384-6-
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for ASTRAZENECA PHARMA

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 10.4, an improvement from the EPS of Rs 8.0 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 1,987.8, stands at 103.9 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 10.9 times, while the price to sales ratio stands at 4.7 times.
  • The company's price to cash flow (P/CF) ratio stood at 122.3 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Sales per share (Unadj.)Rs217.5228.4
TTM Earnings per shareRs8.010.4
Diluted earnings per shareRs8.010.4
Price to Cash Flow x138.5122.3
TTM P/E ratiox103.9103.9
Price / Book Value ratiox11.910.9
Market CapRs m49,69549,695
Dividends per share (Unadj.)Rs0.00.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for ASTRAZENECA PHARMA

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.6x during FY18, from 1.3x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 10.5% during FY18, from 9.0% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 17.7% during FY18, from 15.9% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 5.6% during FY18, from 4.8% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Current ratiox1.31.6
Debtors’ DaysDays2935
Interest coveragex0.00.0
Debt to equity ratiox0.00.0
Return on assets%4.85.6
Return on equity%9.010.5
Return on capital employed%15.917.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how ASTRAZENECA PHARMA has performed over the last 5 years, please visit here.

ASTRAZENECA PHARMA Share Price Performance

Over the last one year, ASTRAZENECA PHARMA share price has moved up from Rs 926.5 to Rs 1,987.8, registering a gain of Rs 1,061.3 or around 114.5%.

(To know more, check out historical annual results for ASTRAZENECA PHARMA and quarterly results for ASTRAZENECA PHARMA)

Equitymaster requests your view! Post a comment on "ASTRAZENECA PHARMA 2017-18 Annual Report Analysis". Click here!

  

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS